Edit of CAR T cells attacking cancer, courtesy of Prasad Adusumilli from Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center’s CAR T Cells: Timeline of Progress
A 10-year summary of CAR T use in blood cancer shows remarkable success. One-third of patients with the most aggressive types of blood cancer remain cancer-free ten years after receiving a single dose of CAR T therapy. Nearly half of those with a slower-growing form of the same lymphoma are also cancer-free. This is beginning to look like a real cure. There is hope now that, as CAR T therapies become more sophisticated and are applied to a wider range of tumors, this very positive result will become the norm.
Patients in the study had already run through standard treatments and had few options left. Their disease had come back or had refused to respond to chemotherapy. A single infusion of engineered T cells, delivered a decade ago, gave them years of life that other therapies could not.
These outcomes reflect a broader shift in how scientists and clinicians think about cancer treatment. The hope is that CAR T, combined with other new therapies, will do the same for many other cancers, changing the entire outlook. What had been, even for the most serious cancers, a near-death sentence may become something people can live with—and, for many, they may be able to live normal lives, without disease.
This shift moves beyond drugs toward living, programmable therapies, a transformation we explore in depth in our recent book, CAR T: A New Cure for Cancer, Autoimmune and Inherited Disease.
What CAR T Therapy Does
CAR T-cell therapy takes a patient’s own immune cells, engineers them in a lab to recognize cancer, and returns them to the body as a living drug. The engineered cell carries a new receptor on its surface. It is tuned to lock onto a marker called CD19 that sits on the outside of B cells, healthy and cancerous alike. Once the engineered cell finds a B cell, it destroys it.
The treatment used was one of the first CAR T therapies approved in the United States. A single infusion is given after a short course of chemotherapy that helps the new cells settle in and multiply. From that point forward, the cells patrol the body and continue to kill cancer as long as any is present.
The Ten-Year Numbers
The team at the University of Pennsylvania followed thirty-eight patients treated at their center. The follow-up time was around 10 years, with some patients tracked for nearly 12 years. All had non-Hodgkin lymphoma, which is a cancer of B cells. Twenty-four had the aggressive form known as large B-cell lymphoma. Fourteen had a slower-growing form of the same lymphoma.
Among the aggressive lymphoma group, 32 percent remained free of lymphoma at 10 years. In the other group, 47 percent remained lymphoma-free, and half were still alive after a decade. For patients who responded to the treatment early on, the picture is even brighter. 54 percent of those with the aggressive form and 60 percent of those with the slower form were still in continuous remission at the 10-year mark.
In this study, Kaplan-Meier curves illustrate when these outcomes stabilize. These curves track the fraction of patients who remain alive or disease-free over time. This type of graph displays how many patients respond and how durable those responses are. A distinct plateau was seen after several years, signaling long-term remission rather than delayed relapse. Perhaps the most striking finding is what did not happen. No new relapses occurred beyond 6 years after treatment. Patients who remained in remission past that point stayed in remission.
Kaplan–Meier curve, modified from the original study, showing overall survival among patients with large B-cell lymphoma and the slower-growing follicular lymphoma.
Adapted From Ruella, M., Paruzzo, L., Chong, E. R., Chong, E. A., Landsburg, D. J., Nasta, S. D., … & Schuster, S. J. (2026). Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. New England Journal of Medicine, 394(24), 2440-2448.
Why This Result Stands Out
Before CAR T therapy, patients with relapsed aggressive lymphoma faced an average survival of about six months. Long-term remission was rare, and the options for those who failed chemotherapy were limited to more chemotherapy or, in some cases, a stem cell transplant that carried heavy risks.
A single infusion that keeps one in three patients alive and free of cancer at ten years is a scale of difference that cancer medicine rarely delivers. The survival curves in the study, the standard way to visualize how long groups of patients survive, show a flat plateau after the five-year mark. This plateau means the deaths and relapses stop. For a cancer that was expected to return within months, a decade of freedom is substantial.
The Trade-Offs
The treatment is not without cost. Nearly half of the long-term responders continued to have low levels of healthy B cells years after the infusion. These low levels are a condition called B-cell aplasia. It leaves patients more vulnerable to infection, and many need regular infusions of antibodies drawn from healthy donors to keep their immune system stable. Some also had lasting drops in blood cell counts.
Nine of the 38 patients developed a second, unrelated cancer during the follow-up period. That number is higher than expected in the general population. It is similar to what other lymphoma survivors face after heavy pretreatment. The finding underscores the need for continued monitoring long after the original cancer is gone.
Even with those caveats, the safety picture over 10 years looks manageable. No new heart, liver, or blood problems appeared late in the follow-up. The immune system slowly rebuilt itself in most patients, and infections did not become a runaway problem.
What This Means for the Field
CAR T therapy can produce lasting remissions, not just temporary responses. It also gives clinicians a clearer picture of what to watch for over the long term, from delayed immune recovery to second cancers.
For patients now being considered for CAR T, the new data change the conversation. What was once framed as a last-line option with unknown durability can now be discussed as a treatment with a real chance of long-term freedom from disease. Newer CAR T products aimed at different cancer markers, and combinations with other immune therapies, are already extending the approach to other blood cancers and beyond.
The next frontier is bringing similar results to solid tumors, where CAR T has so far had limited success. Trials in pancreatic, brain, and lung cancers are underway, and lessons from the 10-year lymphoma experience will help guide them.